10X Genomics Inc vs Under Armour Inc Class A — how do they compare? 10X Genomics Inc trades at $67.8 (market cap $8.55B), while Under Armour Inc Class A trades at $4.79 (market cap $2.15B). The key difference: 10X Genomics Inc is far larger — about 4× Under Armour Inc Class A's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| TXG | UA | |
|---|---|---|
Market Cap | $8.55B | $2.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $67.29 | $7.88 |
52-Week Low | $11.34 | $3.96 |
Enterprise Value | $8.08B | $3.13B |
Signals from Pluang's Aura AI — not financial advice
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Under Armour (UA) trades at $4.95, down 3.32% amid bearish technical signals and weak fundamentals. The stock shows negative profitability with a net income margin of -9.99% and declining revenue trends. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 2026 missing. Cash flow remains negative, and the company faces challenges from softer consumer demand in key markets.
The outlook is cautious due to persistent revenue declines and negative margins. While analyst consensus leans slightly bullish with 40.3% buy ratings, significant risks include execution challenges and competitive pressures. Investors should weigh the potential for a turnaround against ongoing operational headwinds.
Trailing returns across standard periods
Latest headlines on both assets
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →